These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24366412)

  • 1. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.
    Van Allen EM; Foye A; Wagle N; Kim W; Carter SL; McKenna A; Simko JP; Garraway LA; Febbo PG
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):23-7. PubMed ID: 24366412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
    Sailer V; Schiffman MH; Kossai M; Cyrta J; Beg S; Sullivan B; Pua BB; Lee KS; Talenfeld AD; Nanus DM; Tagawa ST; Robinson BD; Rao RA; Pauli C; Bareja R; Beltran LS; Sigaras A; Eng KW; Elemento O; Sboner A; Rubin MA; Beltran H; Mosquera JM
    Cancer; 2018 Mar; 124(5):1008-1015. PubMed ID: 29266381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
    Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
    J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    van Steenbergen TRF; Smits M; Scheenen TWJ; van Oort IM; Nagarajah J; Rovers MM; Mehra N; Fütterer JJ
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):147-154. PubMed ID: 31444628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
    Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
    Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
    Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report.
    Hongo H; Kosaka T; Aimono E; Nishihara H; Oya M
    Diagn Pathol; 2020 Jan; 15(1):5. PubMed ID: 31931827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative clinical genomics of advanced prostate cancer.
    Robinson D; Van Allen EM; Wu YM; Schultz N; Lonigro RJ; Mosquera JM; Montgomery B; Taplin ME; Pritchard CC; Attard G; Beltran H; Abida W; Bradley RK; Vinson J; Cao X; Vats P; Kunju LP; Hussain M; Feng FY; Tomlins SA; Cooney KA; Smith DC; Brennan C; Siddiqui J; Mehra R; Chen Y; Rathkopf DE; Morris MJ; Solomon SB; Durack JC; Reuter VE; Gopalan A; Gao J; Loda M; Lis RT; Bowden M; Balk SP; Gaviola G; Sougnez C; Gupta M; Yu EY; Mostaghel EA; Cheng HH; Mulcahy H; True LD; Plymate SR; Dvinge H; Ferraldeschi R; Flohr P; Miranda S; Zafeiriou Z; Tunariu N; Mateo J; Perez-Lopez R; Demichelis F; Robinson BD; Schiffman M; Nanus DM; Tagawa ST; Sigaras A; Eng KW; Elemento O; Sboner A; Heath EI; Scher HI; Pienta KJ; Kantoff P; de Bono JS; Rubin MA; Nelson PS; Garraway LA; Sawyers CL; Chinnaiyan AM
    Cell; 2015 May; 161(5):1215-1228. PubMed ID: 26000489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
    Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
    Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
    J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.
    Hart SN; Ellingson MS; Schahl K; Vedell PT; Carlson RE; Sinnwell JP; Barman P; Sicotte H; Eckel-Passow JE; Wang L; Kalari KR; Qin R; Kruisselbrink TM; Jimenez RE; Bryce AH; Tan W; Weinshilboum R; Wang L; Kohli M
    BMJ Open; 2016 Apr; 6(4):e010332. PubMed ID: 27084275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
    Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
    J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline and somatic DNA repair gene alterations in prostate cancer.
    Dall'Era MA; McPherson JD; Gao AC; DeVere White RW; Gregg JP; Lara PN
    Cancer; 2020 Jul; 126(13):2980-2985. PubMed ID: 32315455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    Kosaka T; Hongo H; Aimono E; Matsumoto K; Hayashida T; Mikami S; Nishihara H; Oya M
    Pathol Int; 2019 Dec; 69(12):715-720. PubMed ID: 31631483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
    Shenderov E; Isaacsson Velho P; Awan AH; Wang H; Mirkheshti N; Lotan TL; Carducci MA; Pardoll DM; Eisenberger MA; Antonarakis ES
    Prostate; 2019 Sep; 79(13):1572-1579. PubMed ID: 31389628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative Exome Sequencing Analysis in Castration-Resistant Prostate Cancer in Chinese Population.
    Hao L; Li H; Zhang S; Yang Y; Xu Z; Zhang Y; Liu Z
    Curr Pharm Biotechnol; 2020; 21(2):140-148. PubMed ID: 31580249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.